213 related articles for article (PubMed ID: 32143901)
1. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
7. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
8. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
Mendez LC; Arifin AJ; Bauman GS; Velker VM; Ahmad B; Lock M; Venkatesan VM; Sexton TL; Rodrigues GB; Chen J; Schaly B; Warner A; D'Souza DP
BMC Cancer; 2020 Oct; 20(1):978. PubMed ID: 33036579
[TBL] [Abstract][Full Text] [Related]
9. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature.
Francolini G; Detti B; Becherini C; Caini S; Ingrosso G; Di Cataldo V; Stocchi G; Salvestrini V; Lancia A; Scartoni D; Giacomelli I; Sardaro A; Carbonara R; Borghesi S; Aristei C; Livi L
Crit Rev Oncol Hematol; 2021 Sep; 165():103432. PubMed ID: 34352361
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer.
Soni A; Jadhav GK; Manocha S; Chauhan S; Goswami B; Verma M
Rep Pract Oncol Radiother; 2022; 27(6):1001-1009. PubMed ID: 36632300
[TBL] [Abstract][Full Text] [Related]
11. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
12. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
Nossiter J; Sujenthiran A; Cowling TE; Parry MG; Charman SC; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2020 Mar; 38(7):744-752. PubMed ID: 31895608
[TBL] [Abstract][Full Text] [Related]
14. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
[TBL] [Abstract][Full Text] [Related]
15. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Porricelli MA; Muto M; Berretta M; Facchini G; Muto P
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3563-3575. PubMed ID: 28925488
[TBL] [Abstract][Full Text] [Related]
16. Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials.
Lilleby O; Meidahl Petersen P; Daugaard G; Anne Perell K
Scand J Urol; 2023 Jun; 58():21-27. PubMed ID: 37338209
[TBL] [Abstract][Full Text] [Related]
17. Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial.
Park G; Kim YJ; Ahn H; Park W; Lee JS; Kim YS
Trials; 2021 Oct; 22(1):728. PubMed ID: 34674739
[TBL] [Abstract][Full Text] [Related]
18. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
[TBL] [Abstract][Full Text] [Related]
19. Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review.
Neerhut T; Grills R; Lynch R; Preece PD; McLeod K
Urol Oncol; 2024 Jun; 42(6):165-174. PubMed ID: 38503591
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
